Experienced in Sutton Disease 2

Dr. David M. Cognetti

Otolaryngology
Jefferson University Physicians
925 Chestnut St, Fl 6, 
Philadelphia, PA 
Offers Telehealth
Experienced in Sutton Disease 2
Jefferson University Physicians
925 Chestnut St, Fl 6, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical Research

Overview

David Cognetti is an Otolaryngologist in Philadelphia, Pennsylvania. Dr. Cognetti and is rated as an Experienced provider by MediFind in the treatment of Sutton Disease 2. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Sialadenitis, Salivary Duct Stones, Laryngectomy, and Gastrostomy.

His clinical research consists of co-authoring 126 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Otolaryngology
Licenses
Otolaryngology in PA
Hospital Affiliations
Jefferson Stratford Hospital
Pottstown Hospital
Thomas Jefferson University Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

JEFFERSON UNIVERSITY PHYSICIANS
925 Chestnut St, Fl 6, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination with Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination with Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2025
Intervention Type: Combination product, Biological
Study Drugs: Pembrolizumab, Cemiplimab
Study Phase: Phase 1/Phase 2
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug, Combination product
Study Drugs: ASP-1929, Docetaxel, Cetuximab, Methotrexate, Paclitaxel
Study Phase: Phase 3
A Pilot Study Using Surgical Resection and Intraoperative Cesium-131 Permanent Interstitial Brachytherapy Implant in Resectable Recurrent Head and Neck Cancer
A Pilot Study Using Surgical Resection and Intraoperative Cesium-131 Permanent Interstitial Brachytherapy Implant in Resectable Recurrent Head and Neck Cancer
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Drug, Radiation, Procedure
Study Phase: Early Phase 1
A Pilot Trial of a Low-Carbohydrate Normocaloric Diet, in Patients With Head and Neck Carcinoma (HNC) and Its Effect on Stromal-Epithelial Metabolic Uncoupling
A Pilot Trial of a Low-Carbohydrate Normocaloric Diet, in Patients With Head and Neck Carcinoma (HNC) and Its Effect on Stromal-Epithelial Metabolic Uncoupling
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Dietary supplement
Study Phase: Not Applicable
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 08, 2024
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Radiation, Drug
Study Drug: MK-3475
Study Phase: Phase 1
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
Enrollment Status: Completed
Publish Date: February 16, 2024
Intervention Type: Other
A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma
A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma
Enrollment Status: Withdrawn
Publish Date: April 19, 2023
Intervention Type: Combination product, Biological
Study Drugs: RM-1995, Pembrolizumab
Study Phase: Phase 1
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Combination product
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

127 Total Publications

Obesity and Survival After Immune Checkpoint Inhibition for Head and Neck Squamous Cell Carcinoma.
Obesity and Survival After Immune Checkpoint Inhibition for Head and Neck Squamous Cell Carcinoma.
Journal: JAMA otolaryngology-- head & neck surgery
Published: July 03, 2024
Similar Doctors
Advanced in Sutton Disease 2
Dr. Howard S. Landsman
Otolaryngology | Plastic Surgery
Advanced in Sutton Disease 2
Dr. Howard S. Landsman
Otolaryngology | Plastic Surgery

Ear Nose Throat And Facial Plastic Surgery Associates PC

1608 Route 88, Suite 240, 
Brick, NJ 
 (54.7 mi)
732-458-8575
Languages Spoken:
English
See accepted insurances

Howard Landsman is an Otolaryngologist and a Plastic Surgeon in Brick, New Jersey. Dr. Landsman and is rated as an Advanced provider by MediFind in the treatment of Sutton Disease 2. His top areas of expertise are Vertigo, Infant Hearing Loss, Low Nasal Bridge, and Nasal Septal Hematoma.

Advanced in Sutton Disease 2
Dr. Robert I. Park
Otolaryngology
Advanced in Sutton Disease 2
Dr. Robert I. Park
Otolaryngology

Ear, Nose And Throat Group Of Central New Jersey

2124 Oak Tree Rd, 
Edison, NJ 
 (59.6 mi)
732-205-1311
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Park is an Otolaryngologist in Edison, New Jersey. Dr. Park and is rated as a Distinguished provider by MediFind in the treatment of Sutton Disease 2. His top areas of expertise are Ethmoiditis, Otitis, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), and Infant Hearing Loss. Dr. Park is currently accepting new patients.

Experienced in Sutton Disease 2
Dr. Mauritis Boon
Otolaryngology
Experienced in Sutton Disease 2
Dr. Mauritis Boon
Otolaryngology

Jefferson University Physicians

925 Chestnut St, Mezzanine, 
Philadelphia, PA 
215-955-5050
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mauritis Boon is an Otolaryngologist in Philadelphia, Pennsylvania. Dr. Boon and is rated as a Distinguished provider by MediFind in the treatment of Sutton Disease 2. His top areas of expertise are Painful Swallowing, Swallowing Difficulty, Obstructive Sleep Apnea, Spasmodic Dysphonia, and Laryngectomy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile